Alliances

Barry Garfinkel & Associates Consulting LLC

Dr. Garfinkel has over 30 years of experience in the development and manufacture of human vaccines, biologicals and sterile pharmaceuticals from Merck. Dr. Garfinkel is an invaluable resource to Syntiron in the development of viable human vaccine candidates.

Bayside Materials Technology

Mr. Douglas Freitag is the President of Bayside Materials Technology, a company established in 1993 to help companies with federal business development, government affairs, and technology transition. Mr. Freitag serves as Syntiron’s Washington advocate and has been an integral part in developing relationships with NIH, DTRA, NMRC and other important US government agencies. www.baysidematerials.com

DTRA

In October 2008, Syntiron received a $4.1 million contract from the US Defense Threat Reduction Agency (DTRA) for the development of vaccines to protect against three potential bacterial biowarfare agents, including Bacillus anthracis (anthrax), Yersinia pestis (plague), and Burkholderia pseudomallei (melioidosis). www.dtra.mil

Epitopix

Syntiron holds an exclusive license of the Epitopix SRP® technology patent portfolio for all human vaccine applications. Epitopix has proven SRP® Technology to be safe and effective in millions of animals of various species. www.epitopix.com

Frederickson & Byron, PA

Syntiron retains Frederickson & Byron as primary legal counsel. Mr. Ryan Miest serves as Corporate Attorney to Syntiron. Mr. Miest’s practice focuses on representation of technology-driven enterprises ranging from start-ups to publicly-traded corporations in the areas of mergers and acquisitions, corporate finance and securities, strategic intellectual property monetization, and technology transactions. www.fredlaw.com

Meuting, Raasch & Gebhardt, PA

Meuting, Raasch & Gebhardt act as Syntiron's advisors in all issues related to intellectual property law, including patent preparation, prosecution and opinions. www.mrgs.com

NIH

Since 2006, Syntiron has been awarded four Phase I National Institutes of Health (NIH) Small Business Innovation Research grants for the research and development of vaccines against Salmonella spp., Staphylococcus aureus, and Yersinia pestis. www.nih.gov

PharmaNet Development Group (William Eagan, Ph.D.)

PharmaNet and Dr. William Eagan provide Syntiron with expert regulatory consulting services to assist in licensing and commercializing its vaccine products. www.pharmanet.com

sanofi pasteur

In December of 2009, Syntiron granted sanofi pasteur an exclusive world-wide license to its human vaccine against Staphylococcus aureus. The agreement involves joint development of the product and includes an undisclosed initial licensing fee. Altogether, milestone payments that could reach over $149 million in total. Syntiron also stands to receive royalties on future net sales of the product. www.sanofipasteur.com

University of Kentucky

Syntiron is involved in ongoing scientific collaboration with Dr. Robert Perry of the Department of Microbiology and Immunology at the University of Kentucky. Dr. Perry’s laboratory studies the bacterium Yersinia pestis, the causative agent of bubonic and pneumonic plague. www.uky.edu

University of Minnesota

Syntiron’s close ties with the University of Minnesota have resulted in several scientific collaborations with professors, numerous synergistic business relationships with other companies and faculty, and career development opportunities for University students in the Syntiron laboratory. www.umn.edu

US Navy

Syntiron is pleased to have the US Medical Countermeasures and Vaccines Biological Defense Research Directorate at the Naval Medical Research Center (NMRC), as a partner under its US Defense Threat Reduction Agency (DTRA) contract. Syntiron is currently investigating other new and potential biodefense vaccine and therapeutic projects which would also involve the NMRC. www.med.navy.mil/sites/nmrc/Pages/bd_main.htm